Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy

Journal Title: Advances in Hygiene and Experimental Medicine - Year 2012, Vol 66, Issue 0

Abstract

A majority of currently used anticancer drugs belong to a group of chemical agents that damage DNA. The efficiency of the treatment is limited by effective DNA repair systems functioning in cancer cells. Many chemotherapeutic compounds cause strong systemic toxicity. Therefore, there is still a need for new anticancer agents which are less toxic for nontransformed cells and selectively kill cancer cells. One of the most promising molecular targets in cancer therapy is poly(ADP-ribose) polymerases (PARP). PARP play an essential role in repairing DNA strand breaks. Small molecule inhibitors of these enzymes have been developed and have proved to be extremely toxic for cancer cells that lack the functional BRCA1 and BRCA2 proteins that are involved in homologous recombination, a complex repair mechanism of DNA double strand breaks. Mutations in BRCA1/2 genes are associated with genetically inherited breast and ovarian cancers. Therefore PARP inhibitors may prove to be very effective and selective in the treatment of these cancer types. This review is focused on the function of BRCA1/2 proteins and poly(ADP-ribose) polymerases in DNA repair systems, especially in the homologous recombination process. A short history of the studies that led to synthesis of high specificity small molecule PARP inhibitors is also presented, as well as the results of clinical trials concerning the most effective PARP inhibitors in view of their potential application in oncological treatment, particularly breast cancers.

Authors and Affiliations

Katarzyna Kluzek, Aneta Białkowska, Aleksandra Koczorowska, Małgorzata Zdzienicka

Keywords

Related Articles

Potential protective effect of ovocystatin on aging-related cognitive impairment in rats

Introduction: Increased occurrence of cognitive deficits in mild cognitive impairment is related with the phenomenon of aging within the population. Cystatin C has been associated with cysteine protease inhibiting proper...

Ogólnoustrojowe i miejscowe mechanizmy prowadzące do kacheksji w chorobach nowotworowych

Kacheksja to wieloczynnikowy zespół zaniku mięśni szkieletowych i tkanki tłuszczowej, powodujący postępującą utratę masy ciała, związany ze złym rokowaniem w chorobie nowotworowej. Badania przeprowadzone na zwierzęcych m...

Peripheral blood Th17/Treg imbalance in patients with low-active systemic lupus erythematosus

Introduction: The balance between proinflammatory Th17 cells and regulatory T cells plays an important role in the pathogenesis of autoimmune diseases, including systemic lupus erythematosus (SLE). In particular, an incr...

Animal models for the study of Helicobacter pylori infection

The Gram-negative bacillus Helicobacter pylori is widely recognized as a major etiologic agent responsible for chronic active gastritis, peptic ulcers, the development of gastric cancer and mucosa-associated lymphoid tis...

Download PDF file
  • EP ID EP66710
  • DOI -
  • Views 153
  • Downloads 0

How To Cite

Katarzyna Kluzek, Aneta Białkowska, Aleksandra Koczorowska, Małgorzata Zdzienicka (2012). Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy. Advances in Hygiene and Experimental Medicine, 66(0), 372-384. https://europub.co.uk/articles/-A-66710